Dashboard
High Management Efficiency with a high ROCE of 22.52%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.74 times
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 22.52%
Positive results in Sep 26
Stock is technically in a Bullish range
Majority shareholders : Promoters
Stock DNA
Pharmaceuticals & Biotechnology
INR 44,827 Cr (Small Cap)
40.00
40
0.15%
0.31
20.85%
8.36
Total Returns (Price + Dividend) 
Latest dividend: 3 per share ex-dividend date: Aug-14-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2401.5
Surging to an all-time high of Rs 2401.5 on 18 Nov 2026, Emcure Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex. This milestone caps a 74.84% rally over the past year, underscoring the stock’s robust technical underpinnings and sustained upward trajectory.
Read More
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2397.5
Surging to an intraday peak of Rs 2397.5 on 17 Nov 2026, Emcure Pharmaceuticals Ltd has marked a significant milestone by reaching a fresh 52-week high. This rally, driven by a confluence of robust technical indicators and sustained price momentum, underscores the stock’s impressive outperformance against both its sector and the broader market.
Read More
Emcure Pharmaceuticals Ltd is Rated Buy by MarketsMOJO
Emcure Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read More Announcements 
Intimation Of Cancellation Of Schedule Of Analyst/ Investor Meeting(S) Scheduled On November 16 2026
14-Nov-2026 | Source : BSEAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
06-Nov-2026 | Source : BSEIntimation of schedule of Analyst/Investor Meeting dated Monday November 16 2026
Announcement under Regulation 30 (LODR)-Investor Presentation
06-Nov-2026 | Source : BSEIntimation of schedule of Analyst/Investor Meeting on Monday November 16 2026
Corporate Actions 
No Upcoming Board Meetings
Emcure Pharmaceuticals Ltd has declared 36% dividend, ex-date: 04 Sep 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
0.0406
Held by 23 Schemes (7.05%)
Held by 151 FIIs (4.94%)
Satish R Mehta (39.74%)
Kotak Midcap Fund (2.31%)
6.34%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 9.30% vs 4.48% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 10.75% vs 20.78% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 14.49% vs 18.57% in Sep 2024
Growth in half year ended Sep 2025 is 33.00% vs 25.63% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 16.51% vs 18.27% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 38.30% vs 28.55% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -100.00% vs 18.59% in Mar 2025
YoY Growth in year ended Mar 2026 is 35.67% vs 36.76% in Mar 2025